Current attitudes of Canadian urologists towards surgical castration in the treatment of prostate cancer.
作者信息
Anderson Patrick T, Rowe Neal E
机构信息
Department of Surgery, Division of Urology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
出版信息
Can Urol Assoc J. 2021 May;15(5):E281-E285. doi: 10.5489/cuaj.6834.
Abstract
摘要
相似文献
1
Current attitudes of Canadian urologists towards surgical castration in the treatment of prostate cancer.加拿大泌尿外科医生对手术去势治疗前列腺癌的当前态度。
Can Urol Assoc J. 2021 May;15(5):E281-E285. doi: 10.5489/cuaj.6834.
2
Changing attitudes towards management of men with locally advanced prostate cancer following radical prostatectomy: A follow-up survey of Australia-based urologists.根治性前列腺切除术后对局部晚期前列腺癌男性患者管理态度的转变：对澳大利亚泌尿外科医生的随访调查
J Med Imaging Radiat Oncol. 2016 Dec;60(6):744-755. doi: 10.1111/1754-9485.12483. Epub 2016 Jun 27.
3
Knowledge, attitudes and beliefs towards management of men with locally advanced prostate cancer following radical prostatectomy: an Australian survey of urologists.对根治性前列腺切除术后局部晚期前列腺癌男性患者管理的知识、态度和信念：澳大利亚泌尿外科医生调查
BJU Int. 2016 Apr;117 Suppl 4:35-44. doi: 10.1111/bju.13037.
4
5
Differences between urologists in the United States and Canada in the approach to prostate cancer.美国和加拿大泌尿外科医生在前列腺癌治疗方法上的差异。
J Urol. 2000 May;163(5):1461-6.
6
De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT).取消前列腺癌男性的低价值阉割：基于理论的、混合方法的最小化低价值雄激素剥夺治疗（DeADT）的方案。
Implement Sci. 2018 Nov 29;13(1):144. doi: 10.1186/s13012-018-0833-7.
7
Current management of advanced and castration resistant prostate cancer.晚期及去势抵抗性前列腺癌的当前管理
Can J Urol. 2014 Apr;21(2 Supp 1):1-6.
8
Bone scan use in the management of metastatic castration-resistant prostate cancer: Survey of practice patterns among Canadian radiation oncologists, medical oncologists, and urologists.骨扫描在转移性去势抵抗性前列腺癌管理中的应用：加拿大放射肿瘤学家、医学肿瘤学家和泌尿科医生的实践模式调查
Can Urol Assoc J. 2020 Nov;14(11):E601-E603. doi: 10.5489/cuaj.6320.
9
The role of the urologist in treating patients with hormone-refractory prostate cancer.泌尿科医生在治疗激素难治性前列腺癌患者中的作用。
Rev Urol. 2003;5 Suppl 2(Suppl 2):S48-52.
10
Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists.医生对局限性前列腺癌基因检测的态度：一项针对放射肿瘤学家和泌尿科医生的全国性调查。
Urol Oncol. 2018 Nov;36(11):501.e15-501.e21. doi: 10.1016/j.urolonc.2018.07.002. Epub 2018 Sep 3.
引用本文的文献
1
Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study.雄激素剥夺治疗的前列腺癌患者心血管负担的时间趋势：基于人群的队列研究。
Br J Cancer. 2023 Jun;128(12):2253-2260. doi: 10.1038/s41416-023-02271-5. Epub 2023 Apr 19.
2
What Is Your Choice for Androgen Deprivation Therapy in Metastatic Prostate Carcinoma: Surgical or Medical?转移性前列腺癌雄激素剥夺治疗的选择：手术还是药物？
Turk J Urol. 2022 Jul;48(4):287-293. doi: 10.5152/TJU.2022.22076.
本文引用的文献
1
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.晚期前列腺癌：AUA/ASTRO/SUO 指南 PART I.
J Urol. 2021 Jan;205(1):14-21. doi: 10.1097/JU.0000000000001375. Epub 2020 Sep 22.
2
Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.雄激素剥夺治疗去势敏感性前列腺癌期间的睾酮突破性进展率。
J Urol. 2020 Sep;204(3):416-426. doi: 10.1097/JU.0000000000000809. Epub 2020 Feb 25.
3
Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.加拿大泌尿外科学会 - 加拿大泌尿肿瘤学组关于转移性去势初治和去势敏感性前列腺癌的指南
Can Urol Assoc J. 2020 Feb;14(2):17-23. doi: 10.5489/cuaj.6384. Epub 2019 Dec 5.
4
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.黄体生成素释放激素激动剂给药时间对前列腺癌患者睾酮抑制的影响：美国临床数据分析。
J Urol. 2020 Apr;203(4):743-750. doi: 10.1097/JU.0000000000000577. Epub 2019 Oct 3.
5
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.ARCHES：雄激素剥夺治疗联合恩扎卢胺或安慰剂治疗转移性去势敏感性前列腺癌的随机 III 期研究。
J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22.
6
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.恩扎卢胺联合标准一线治疗转移性前列腺癌。
N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.
7
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.《前列腺癌（2019 年版）》，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.
8
Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies.前列腺癌统计数据、分级、诊断和治疗策略简介。
Adv Exp Med Biol. 2018;1095:1-14. doi: 10.1007/978-3-319-95693-0_1.
9
Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.了解前列腺癌患者如何看待转移性去势抵抗性前列腺癌的当前治疗选择。
Urol Oncol. 2018 May;36(5):240.e13-240.e20. doi: 10.1016/j.urolonc.2018.01.011. Epub 2018 Feb 15.
10
Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.转移性前列腺癌（mPC）的治疗方法：成本证据综述。
Pharmacoeconomics. 2017 Dec;35(12):1223-1236. doi: 10.1007/s40273-017-0555-8.
Zotero 插件